Tag Archives: Zytiga

Genentech Acquires Seragon – Selective Estrogen Receptor Degraders for breast cancer

Roche /Genentech announced that it acquired a company called Seragon for its new class of compound РSERD (selective Estrogen Receptor Degraders).  Blocking estrogen production (aromatse inhibitors) and the binding to the estrogen receptor (tamoxifen) are mainstays of treatment for patients with ER (estrogen receptor) and PR (progesterone receptor) positive breast cancer.  However, patients relapse subsequent to treatment with these agents. Continue reading